202 related articles for article (PubMed ID: 27909306)
1. RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response.
Hofman IJF; van Duin M; De Bruyne E; Fancello L; Mulligan G; Geerdens E; Garelli E; Mancini C; Lemmens H; Delforge M; Vandenberghe P; Wlodarska I; Aspesi A; Michaux L; Vanderkerken K; Sonneveld P; De Keersmaecker K
Leukemia; 2017 Aug; 31(8):1706-1714. PubMed ID: 27909306
[TBL] [Abstract][Full Text] [Related]
2. A new region of synteny between human chromosome 1p22 and mouse chromosome 5.
Chelsea DM; Roberts T; Cowell JK
Int J Mol Med; 2000 May; 5(5):553-6. PubMed ID: 10762661
[TBL] [Abstract][Full Text] [Related]
3. Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma.
Duru AD; Sutlu T; Wallblom A; Uttervall K; Lund J; Stellan B; Gahrton G; Nahi H; Alici E
PLoS One; 2015; 10(9):e0138248. PubMed ID: 26378933
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic Impact of 1q21 Amplification in Newly Diagnosed Multiple Myeloma Patients Receiving Bortezomib-Based First-Line Treatment].
Deng P; Zhou YL; Wei YL; Li P; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1696-1701. PubMed ID: 29262900
[TBL] [Abstract][Full Text] [Related]
5. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Smetana J; Berankova K; Zaoralova R; Nemec P; Greslikova H; Kupska R; Mikulasova A; Frohlich J; Sevcikova S; Zahradova L; Krejci M; Sandecka V; Almasi M; Kaisarova P; Melicharova H; Adam Z; Penka M; Jarkovsky J; Jurczyszyn A; Hajek R; Kuglik P
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):123-30. PubMed ID: 23291040
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.
Sagaster V; Ludwig H; Kaufmann H; Odelga V; Zojer N; Ackermann J; Küenburg E; Wieser R; Zielinski C; Drach J
Leukemia; 2007 Jan; 21(1):164-8. PubMed ID: 17096015
[TBL] [Abstract][Full Text] [Related]
8. Tag-SNP analysis of the GFI1-EVI5-RPL5-FAM69 risk locus for multiple sclerosis.
Alcina A; Fernández O; Gonzalez JR; Catalá-Rabasa A; Fedetz M; Ndagire D; Leyva L; Guerrero M; Arnal C; Delgado C; Lucas M; Izquierdo G; Matesanz F
Eur J Hum Genet; 2010 Jul; 18(7):827-31. PubMed ID: 20087403
[TBL] [Abstract][Full Text] [Related]
9. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Chen MH; Qi C; Reece D; Chang H
Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.
Wang H; Meng H; Wang J; Lou Y; Zhou Y; Lin P; Li F; Liu L; Xu H; Yang M; Jin J
Front Med; 2020 Jun; 14(3):327-334. PubMed ID: 31784918
[TBL] [Abstract][Full Text] [Related]
11. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.
Boyd KD; Ross FM; Walker BA; Wardell CP; Tapper WJ; Chiecchio L; Dagrada G; Konn ZJ; Gregory WM; Jackson GH; Child JA; Davies FE; Morgan GJ;
Clin Cancer Res; 2011 Dec; 17(24):7776-84. PubMed ID: 21994415
[TBL] [Abstract][Full Text] [Related]
12. The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD).
Terragna C; Remondini D; Martello M; Zamagni E; Pantani L; Patriarca F; Pezzi A; Levi G; Offidani M; Proserpio I; De Sabbata G; Tacchetti P; Cangialosi C; Ciambelli F; Viganò CV; Dico FA; Santacroce B; Borsi E; Brioli A; Marzocchi G; Castellani G; Martinelli G; Palumbo A; Cavo M
Oncotarget; 2016 Mar; 7(9):9666-79. PubMed ID: 26575327
[TBL] [Abstract][Full Text] [Related]
13. [Influence of Chromosome Abnormality on Therapeutic Efficacy and Prognosis of Newly Diagnosed Multiple Myeloma Treated with Bortezomib].
Sun C; Wang J; Guo HF; Zhou X; Shen YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):142-146. PubMed ID: 28245391
[TBL] [Abstract][Full Text] [Related]
14. The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib.
Robak P; Jarych D; Mikulski D; Dróżdż I; Węgłowska E; Kotkowska A; Misiewicz M; Smolewski P; Stawiski K; Fendler W; Szemraj J; Robak T
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668794
[TBL] [Abstract][Full Text] [Related]
15. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients.
Hebraud B; Leleu X; Lauwers-Cances V; Roussel M; Caillot D; Marit G; Karlin L; Hulin C; Gentil C; Guilhot F; Garderet L; Lamy T; Brechignac S; Pegourie B; Jaubert J; Dib M; Stoppa AM; Sebban C; Fohrer C; Fontan J; Fruchart C; Macro M; Orsini-Piocelle F; Lepeu G; Sohn C; Corre J; Facon T; Moreau P; Attal M; Avet-Loiseau H
Leukemia; 2014 Mar; 28(3):675-9. PubMed ID: 23892719
[TBL] [Abstract][Full Text] [Related]
16. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.
Mulligan G; Lichter DI; Di Bacco A; Blakemore SJ; Berger A; Koenig E; Bernard H; Trepicchio W; Li B; Neuwirth R; Chattopadhyay N; Bolen JB; Dorner AJ; van de Velde H; Ricci D; Jagannath S; Berenson JR; Richardson PG; Stadtmauer EA; Orlowski RZ; Lonial S; Anderson KC; Sonneveld P; San Miguel JF; Esseltine DL; Schu M
Blood; 2014 Jan; 123(5):632-9. PubMed ID: 24335104
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
18. Early tumor-cell gene expression changes may predict the response to first-line bortezomib-based therapy in patients with newly diagnosed multiple myeloma.
Liapis K; Kastritis E; Bagratouni T; Vassiliou S; Papachristidis A; Charitaki E; Alevizopoulos N; Harhalakis N; Terpos E; Delimpasi S; Dimopoulos MA
J BUON; 2015; 20(5):1314-21. PubMed ID: 26537080
[TBL] [Abstract][Full Text] [Related]
19. Protein Kinase D 1 Predicts Poor Treatment Response and Unfavorable Survival of Bortezomib-Based Treatment, and Its Knockdown Enhances Drug Sensitivity to Bortezomib in Multiple Myeloma.
Li X; Yang Y; Yi X
Technol Cancer Res Treat; 2020; 19():1533033820936770. PubMed ID: 32799769
[TBL] [Abstract][Full Text] [Related]
20. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.
Ling SC; Lau EK; Al-Shabeeb A; Nikolic A; Catalano A; Iland H; Horvath N; Ho PJ; Harrison S; Fleming S; Joshua DE; Allen JD
Haematologica; 2012 Jan; 97(1):64-72. PubMed ID: 21993678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]